Suppr超能文献

在无血清条件下体外生成单核细胞来源的巨噬细胞可提高其促肿瘤功能。

In vitro generation of monocyte-derived macrophages under serum-free conditions improves their tumor promoting functions.

机构信息

Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany.

出版信息

PLoS One. 2012;7(8):e42656. doi: 10.1371/journal.pone.0042656. Epub 2012 Aug 6.

Abstract

The tumor promoting role of M2 macrophages has been described in in vivo models and the presence of macrophages in certain tumor types has been linked to a poor clinical outcome. In light of burgeoning activities to clinically develop new therapies targeting tumor-associated macrophages (TAMs), reliable in vitro models faithfully mimicking the tumor promoting functions of TAMs are required. Generation and activation of human monocyte-derived macrophages (MDM) in vitro, described as M1 or M2 macrophages attributed with tumoricidal or tumor-promoting functions, respectively, has been widely reported using mainly serum containing culture methods. In this study, we compared the properties of macrophages originating from monocytes cultured either in media containing serum together with M-CSF for M2 and GM-CSF for M1 macrophages or in serum-free media supplemented with M-CSF or GM-CSF and cytokines such as IL-4, IL-10 to induce activated M2 or LPS together with IFN-γ to generate activated M1 phenotype. We observed differences in cell morphology as well as increased surface receptor expression levels in serum-containing culture whereas similar or higher cytokine production levels were detected under serum-free culture conditions. More importantly, MDM differentiated under serum-free conditions displayed enhanced tumoricidal activity for M1 and tumor promoting property for M2 macrophages in contrast to MDM differentiated in the presence of serum. Moreover, evaluation of MDM phagocytic activity in serum free condition resulted in greater phagocytic properties of M2 compared to M1. Our data therefore confirm the tumor promoting properties of M2 macrophages in vitro and encourage the targeting of TAMs for cancer therapy.

摘要

M2 巨噬细胞在体内模型中具有促进肿瘤的作用,某些肿瘤类型中存在巨噬细胞与不良的临床结果相关。鉴于针对肿瘤相关巨噬细胞(TAMs)的新疗法的临床开发活动不断增加,因此需要能够真实模拟 TAMs 促进肿瘤功能的可靠体外模型。体外生成和激活人单核细胞来源的巨噬细胞(MDM),分别描述为具有细胞毒性或促进肿瘤作用的 M1 或 M2 巨噬细胞,已经广泛报道使用主要含有血清的培养方法。在这项研究中,我们比较了在含有血清的培养基中培养的巨噬细胞(用于 M2 的 M-CSF 和用于 M1 的 GM-CSF)与在无血清培养基中培养的巨噬细胞的特性,该培养基补充有 M-CSF 或 GM-CSF 以及细胞因子(如 IL-4、IL-10 以诱导激活的 M2 或 LPS 与 IFN-γ 一起产生激活的 M1 表型。我们观察到在含有血清的培养条件下细胞形态以及表面受体表达水平的差异,而在无血清培养条件下检测到相似或更高的细胞因子产生水平。更重要的是,与在有血清的条件下分化的 MDM 相比,在无血清条件下分化的 MDM 显示出增强的 M1 细胞毒性活性和 M2 肿瘤促进特性。此外,在无血清条件下评估 MDM 的吞噬活性导致 M2 的吞噬特性大于 M1。因此,我们的数据证实了 M2 巨噬细胞在体外的促进肿瘤作用,并鼓励针对癌症治疗的 TAMs 靶向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02ca/3412794/e395d9cb8980/pone.0042656.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验